MarketPulse

oral therapy

4 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Alumis' Psoriasis Drug Shows Strong Phase 3 Results, Paving Way for 2026 FDA Filing

Alumis reports positive Phase 3 results for envudeucitinib, achieving 68% PASI 90 skin clearance in plaque psoriasis patients, with FDA filing planned for late 2026.
ALMSquality of lifeTYK2 inhibitor
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Sitryx to Showcase Autoimmune Pipeline at Four Major Biopharma Conferences in April

Clinical-stage biotech Sitryx Therapeutics will present at four investor conferences in April 2026, highlighting its oral autoimmune and inflammatory disease therapies.
LLYGSKoral therapyinvestor conference
GlobeNewswire Inc.GlobeNewswire Inc.··Nodthera

NodThera to Present NLRP3 Drug Program at Major April Investor Conferences

NodThera, a clinical-stage NLRP3 inhibitor biotech, will present at major April 2026 investor conferences including Piper Sandler and Needham.
SNYoral therapyclinical-stage biotech
GlobeNewswire Inc.GlobeNewswire Inc.··Spherix Global Insights

Rheumatologists Split on Sotyktu's Market Impact Ahead of FDA Decision

BMS's Sotyktu shows promise for psoriatic arthritis among one-third of surveyed rheumatologists, but analysts expect modest market capture ahead of March 2026 FDA decision.
AMGNBMYCELGrJNJPFE+1psoriatic arthritisTYK2 inhibitor